Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 4c, Updates FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
Go back to Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 4c, Updates FY Guidance
November 10, 2015 10:20 AM EST
Jazz reported a slightly disappointing Q3 with revenue of $340.9M, missing consensus by $7M. Non-GAAP EPS for the Q was $2.52, below consensus of $2.56.
Full-year guidance was narrowed slightly but it's more toward the lower end of the range given in Q2. Canaccord Genuity analyst, Corey Davis, noted that... More
November 10, 2015 9:51 AM EST
Piper Jaffray reiterated an Overweight rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $186.00 (from $208.00), following the company's 3Q earnings report. Jazz reported non-GAAP EPS of $2.52 on revenues of $341M, largely in-line with the Street estimates of $2.56 and $348M, respectively. Xyrem sales totaled $243M, up from $204M in 3Q14, with annual volume... More
November 10, 2015 8:42 AM EST
Leerink Partners maintained an Outperform rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $187.00 (from $220.00), following the company's 3Q earnings report. JAZZs update included a modest topline miss driven by slower patient volume growth as the company experienced delays in Xyrem refills.
Analyst Jason... More
November 10, 2015 6:31 AM EST
Mizuho Securities downgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Outperform to Neutral with a price target of $140.00 (from $164.00) on valuation.
Analyst Irina Koffler commented, "We are downgrading Jazz to NEUTRAL from BUY and lowering our PT from $164 to $140 on revised valuation methodology.... More
